Dissolution Rate Enhancement, Design and Development of Buccal Drug Delivery of Darifenacin Hydroxypropyl β-Cyclodextrin Inclusion Complexes

Table 5

Evaluation of HPMC K100CR patches.

Formulation code	Thickness (mm)	Weight uniformity (mg)	Surface pH	Content uniformity (%)	In vitro drug release (%) (10 hrs)	Swelling index (% weight increase after 3 hrs)
Hb1	0.69±0.05	58.69±0.87	6.13±0.059	91.86±1.57	84.51±1.863	38.45±0.43
Hb2	0.85±0.07	68.63±0.676	6.66±0.085	95.93±2.3	92.487±2.04	39.57±1.78
Hb3	0.82±0.12	71.56±0.536	6.21±0.07	93.28±1.45	75.42±1.487	44.01±1.88
Hb4	0.87±0.04	75.41±0.674	5.54±0.075	100.22±3.16	64.31±2.32	46.75±2.73
Hb5	1.08±0.21	79.82±0.615	5.92±0.065	90.38±1.22	66.02±2.24	49.48±3.04